Article
Pharmacogenetic mechanism of cilostazol-induced headaches: Splicing-mediated loss of ABCC5 gene function.
British journal of pharmacology - 1 Oct 2026
Lee Sung Hee, Kim So Myoung, Lee Dong-Hwan, Hasanuzzaman Md, Park Danbi, Rahaman Md Intazur, Lee Seokil, Gu Yongchul, Kim Hye Won, Park Wonhee, Kim Hyunho, Bang Woo-Dae, Park Joonhee, Park Yejin, Park Hyun June, Lee Jinu, Cho Sung Kweon, Park Kyungsoo, Lee Min Goo, Lee Ji Hyun, Lee Eun-Jae, Kim So Won
Abstract excerpt
BACKGROUND AND PURPOSE: Cilostazol, a phosphodiesterase 3 inhibitor, causes intolerable headaches in over one third of patients, frequently leading to treatment discontinuation. We investigated whether ABCC5 variant rs7636910 (NM_005688.4:c.1146A > G) protects against cilostazol-induced headaches through altered cyclic nucleotide signalling. EXPERIMENTAL APPROACH: Analysis included 101 healthy Korean volunteers...
Read the complete abstract on PubMed